Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02268526 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of CSJ148 in Stem Cell Transplant Patients
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 86
- Enrollment target
NCT02268526: Completed Phase 2 study, sponsored by Novartis Pharmaceuticals.
NCT02268526 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 86 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (35% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02268526, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 86 participants
- Enrollment target
Study Summary
This study is designed to test if CSJ148 can prevent HCMV replication after stem cell transplantation.
Primary Outcome
Number of participants who require preemptive HCMV therapy. The definition of requiring preemptive anti-HCMV therapy was meeting either one of the following conditions: 1. the plasma HCMV DNA level is \>= 1000 copies/mL (with or without HCMV disease) or 2. the plasma HCMV DNA level is \< 1000 copies/mL, but HCMV disease was reported
Interventions
- DRUG Placebo
- BIOLOGICAL CSJ148
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2015-06-02 |
| Est. Completion | 2016-12-07 |
| Phase | Phase 2 |
What the finished NCT02268526 record still lists
NCT02268526 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 86 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (35% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02268526 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02268526 about?
NCT02268526 is a clinical study titled "Efficacy and Safety Study of CSJ148 in Stem Cell Transplant Patients". This study is designed to test if CSJ148 can prevent HCMV replication after stem cell transplantation.
What is the current status of trial NCT02268526?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 86 participants. The study started on 2015-06-02. Estimated completion is 2016-12-07.
What interventions are being tested in trial NCT02268526?
The interventions under investigation include: Placebo (DRUG), CSJ148 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02268526?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02268526's enrollment target sits among peer trials
86 812th of 2000 higher than 1,181 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01639508 · 86 participants · Phase 2
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
- NCT03519269 · 86 participants · NA
Navio Robotic Versus Conventional Total Knee Arthroplasty
- NCT04132999 · 86 participants · NA
PAP for Children With DS and OSAS
- NCT04545957 · 86 participants · NA
Jump: MR Simulation For Radiation Therapy Master Protocol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI